Drug Evaluation, Preclinical
"Drug Evaluation, Preclinical" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Preclinical testing of drugs in experimental animals or in vitro for their biological and toxic effects and potential clinical applications.
| Descriptor ID |
D004353
|
| MeSH Number(s) |
E05.295.750 E05.337.550
|
| Concept/Terms |
Drug Evaluation, Preclinical- Drug Evaluation, Preclinical
- Drug Evaluations, Preclinical
- Drug Screening
- Drug Screenings
- Screening, Drug
- Screenings, Drug
- Evaluation Studies, Drug, Pre-Clinical
- Preclinical Drug Evaluations
- Evaluation, Preclinical Drug
- Evaluations, Preclinical Drug
- Preclinical Drug Evaluation
- Drug Evaluation Studies, Preclinical
- Evaluation Studies, Drug, Preclinical
|
Below are MeSH descriptors whose meaning is more general than "Drug Evaluation, Preclinical".
Below are MeSH descriptors whose meaning is more specific than "Drug Evaluation, Preclinical".
This graph shows the total number of publications written about "Drug Evaluation, Preclinical" by people in this website by year, and whether "Drug Evaluation, Preclinical" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1994 | 0 | 3 | 3 |
| 1996 | 0 | 4 | 4 |
| 1997 | 0 | 1 | 1 |
| 1998 | 0 | 1 | 1 |
| 1999 | 0 | 6 | 6 |
| 2000 | 1 | 5 | 6 |
| 2001 | 1 | 7 | 8 |
| 2002 | 0 | 7 | 7 |
| 2003 | 2 | 7 | 9 |
| 2004 | 2 | 4 | 6 |
| 2005 | 4 | 5 | 9 |
| 2006 | 4 | 11 | 15 |
| 2007 | 0 | 15 | 15 |
| 2008 | 1 | 20 | 21 |
| 2009 | 2 | 19 | 21 |
| 2010 | 0 | 22 | 22 |
| 2011 | 1 | 19 | 20 |
| 2012 | 3 | 13 | 16 |
| 2013 | 3 | 16 | 19 |
| 2014 | 3 | 17 | 20 |
| 2015 | 1 | 11 | 12 |
| 2016 | 1 | 13 | 14 |
| 2017 | 1 | 11 | 12 |
| 2018 | 4 | 14 | 18 |
| 2019 | 1 | 8 | 9 |
| 2020 | 3 | 3 | 6 |
| 2021 | 2 | 6 | 8 |
| 2023 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Drug Evaluation, Preclinical" by people in Profiles.
-
Drug screening identifies tazarotene and bexarotene as therapeutic agents in multiple sulfatase deficiency. EMBO Mol Med. 2023 03 08; 15(3):e14837.
-
Evaluation of an EZH2 inhibitor in patient-derived orthotopic xenograft models of pediatric brain tumors alone and in combination with chemo- and radiation therapies. Lab Invest. 2022 02; 102(2):185-193.
-
Emerging Importance of Tyrosine Kinase Inhibitors against Cancer: Quo Vadis to Cure? Int J Mol Sci. 2021 Oct 28; 22(21).
-
Spike protein recognizer receptor ACE2 targeted identification of potential natural antiviral drug candidates against SARS-CoV-2. Int J Biol Macromol. 2021 Nov 30; 191:1114-1125.
-
Pretransplant Short-Term Exposure of Donor Graft Cells to ITK Selective Inhibitor Ameliorates Acute Graft-versus-Host Disease by Inhibiting Effector T Cell Differentiation while Sparing Regulatory T Cells. Immunohorizons. 2021 06 10; 5(6):424-437.
-
Engineering 'Enzymelink' for screening lead compounds to inhibit mPGES-1 while maintaining prostacyclin synthase activity. Future Med Chem. 2021 07; 13(13):1091-1103.
-
Translational pharmacokinetic-pharmacodynamic modeling of preclinical and clinical data of the oral MET inhibitor tepotinib to determine the recommended phase II dose. CPT Pharmacometrics Syst Pharmacol. 2021 05; 10(5):428-440.
-
Novel STAT3 small-molecule inhibitors identified by structure-based virtual ligand screening incorporating SH2 domain flexibility. Pharmacol Res. 2021 07; 169:105637.
-
Discovery of a Vitamin D Receptor-Silent Vitamin D Derivative That Impairs Sterol Regulatory Element-Binding Protein In Vivo. J Med Chem. 2021 05 13; 64(9):5689-5709.
-
Lead compounds for the development of SARS-CoV-2 3CL protease inhibitors. Nat Commun. 2021 04 01; 12(1):2016.